Enhanced anti-tumor efficacy through a combination of integrin αvβ6-targeted photodynamic therapy and immune checkpoint inhibition

Theranostics

Volumn 6, Issue 5, 2016, Pages 627-637

  Gao, Liquan ^a   Zhang, Chenran ^a   Gao, Duo ^a   Liu, Hao ^a   Yu, Xinhe ^a   Lai, Jianhao ^a   Wang, Fan ^a   Lin, Jian ^b   Liu, Zhaofei ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Checkpoint inhibition; Combination therapy; Molecular imaging; Photodynamic therapy; Tumor metastasis

Indexed keywords

ALPHAVBETA6 INTEGRIN; CYTOKINE; FIREFLY LUCIFERASE; IRDYE700 STREPTAVIDIN BIOTIN HK PEPTIDE; PHOTOSENSITIZING AGENT; PHTHALOCYANINE; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; INDOLE DERIVATIVE; INTEGRIN; PDCD1 PROTEIN, MOUSE; RADIOSENSITIZING AGENT; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; BREAST CANCER; CANCER INHIBITION; CANCER MODEL; CD8+ T LYMPHOCYTE; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG TARGETING; FEMALE; FLUORESCENCE IMAGING; GENETIC TRANSFECTION; LIGHT; LUNG METASTASIS; METASTASIS; METASTASIS INHIBITION; NONHUMAN; PHOTODYNAMIC THERAPY; PRIMARY TUMOR; TUMOR IMMUNITY; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CYTOTOXICITY; DISEASE MODEL; LUNG NEOPLASMS; METABOLISM; MOUSE; PHOTOCHEMOTHERAPY; PROCEDURES; SECONDARY; TREATMENT OUTCOME;

ANIMALS; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; IMMUNOLOGIC FACTORS; INDOLES; INTEGRINS; LIGHT; LUNG NEOPLASMS; MICE; PHOTOCHEMOTHERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; RADIATION-SENSITIZING AGENTS; TREATMENT OUTCOME;

EID: 84964336979     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.14792     Document Type: Article

References (37)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3: e442.
2. Schroeder A, Heller DA, Winslow MM, et al. Treating metastatic cancer with nanotechnology. Nat Rev Cancer. 2012; 12: 39-50.
3. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006; 12: 895-904.
4. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006; 127: 679-95.
5. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science. 2004; 305: 200-5.
6. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011; 480: 480-9.
7. Wherry EJ. T cell exhaustion. Nat Immunol. 2011; 12: 492-9.
8. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12: 252-64.
9. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-23.
10. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012; 12: 237-51.
11. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366: 2443-54.
12. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013; 369: 134-44.
13. Yuan A, Wu J, Tang X, et al. Application of near-infrared dyes for tumor imaging, photothermal, and photodynamic therapies. J Pharm Sci. 2013; 102: 6-28.
14. Sato K, Nagaya T, Choyke PL, et al. Near infrared photoimmunotherapy in the treatment of pleural disseminated NSCLC: preclinical experience. Theranostics. 2015; 5: 698-709.
15. Sato K, Hanaoka H, Watanabe R, et al. Near infrared photoimmunotherapy in the treatment of disseminated peritoneal ovarian cancer. Mol Cancer Ther. 2015; 14: 141-50.
16. Mitsunaga M, Ogawa M, Kosaka N, et al. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med. 2011; 17: 1685-91.
17. Nakajima T, Sano K, Choyke PL, et al. Improving the efficacy of Photoimmunotherapy (PIT) using a cocktail of antibody conjugates in a multiple antigen tumor model. Theranostics. 2013; 3: 357-65.
18. Gao D, Gao L, Zhang C, et al. A near-infrared phthalocyanine dye-labeled agent for integrin alphavbeta6-targeted theranostics of pancreatic cancer. Biomaterials. 2015; 53: 229-38.
19. van Duijnhoven FH, Aalbers RI, Rovers JP, et al. The immunological consequences of photodynamic treatment of cancer, a literature review. Immunobiology. 2003; 207: 105-13.
20. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer. 2006; 6: 535-45.
21. Liu Z, Yu Z, He W, et al. In-vitro internalization and in-vivo tumor uptake of anti-EGFR monoclonal antibody LA22 in A549 lung cancer cells and animal model. Cancer Biother Radiopharm. 2009; 24: 15-24.
22. Gao L, Liu H, Sun X, et al. Molecular imaging of post-Src-inhibition tumor signatures for guiding dasatinib combination therapy. J Nucl Med. 2016; 57: 321-326.
23. Liu Z, Sun X, Liu H, et al. Early assessment of tumor response to gefitinib treatment by noninvasive optical imaging of tumor vascular endothelial growth factor expression in animal models. J Nucl Med. 2014; 55: 818-23.
24. Zhang C, Gao L, Cai Y, et al. Inhibition of tumor growth and metastasis by photoimmunotherapy targeting tumor-associated macrophage in a sorafenib-resistant tumor model. Biomaterials. 2016; 84: 1-12.
25. Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010; 107: 4275-80.
26. Sun X, Gao D, Gao L, et al. Molecular imaging of tumor-infiltrating macrophages in a preclinical mouse model of breast cancer. Theranostics. 2015; 5: 597-608.
27. Liu Z, Liu H, Ma T, et al. Integrin αvβ6-targeted SPECT imaging for pancreatic cancer detection. J Nucl Med. 2014; 55: 989-94.
28. Bandyopadhyay A, Raghavan S. Defining the role of integrin avβ6 in cancer. Curr Drug Targets. 2009; 10: 645-52.
29. Berchtold S, Muhl-Zurbes P, Heufler C, et al. Cloning, recombinant expression and biochemical characterization of the murine CD83 molecule which is specifically upregulated during dendritic cell maturation. FEBS Lett. 1999; 461: 211-6.
30. Wesa AK, Galy A. IL-1 beta induces dendritic cells to produce IL-12. Int Immunol. 2001; 13: 1053-61.
31. Waitz R, Solomon SB, Petre EN, et al. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res. 2012; 72: 430-9.
32. Wang C, Xu L, Liang C, et al. Immunological responses triggered by photothermal therapy with carbon nanotubes in combination with anti-CTLA-4 therapy to inhibit cancer metastasis. Adv Mater. 2014; 26: 8154-62.
33. Vanpouille-Box C, Diamond JM, Pilones KA, et al. TGFβ is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res. 2015; 75: 2232-42.
34. Keir ME, Francisco LM, Sharpe AH. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol. 2007; 19: 309-14.
35. Inoue Y, Izawa K, Kiryu S, et al. Diet and abdominal autofluorescence detected by in vivo fluorescence imaging of living mice. Mol Imaging. 2008; 7: 21-7.
36. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369: 122-33.
37. Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015; 520: 373-7.